RNASE9
Inactive ribonuclease-like protein 9
Also known as: h461, RAK1, RNAS9_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P60153
- Gene
- RNASE9
- Ensembl
- ENSG00000188655
- Chromosome
- 14
- Canonical length
- 205 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Predicted to enable nucleic acid binding activity. Predicted to be involved in defense response to Gram-positive bacterium. Predicted to act upstream of or within positive regulation of flagellated sperm motility involved in capacitation. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
205 residues, UniProt reviewed canonical sequence.
>P60153|RNASE9
1 MMRTLITTHP LPLLLLPQQL LQLVQFQEVD TDFDFPEEDK KEEFEECLEK FFSTGPARPP
61 TKEKVKRRVL IEPGMPLNHI EYCNHEIMGK NVYYKHRWVA EHYFLLMQYD ELQKICYNRF
121 VPCKNGIRKC NRSKGLVEGV YCNLTEAFEI PACKYESLYR KGYVLITCSW QNEMQKRIPH
181 TINDLVEPPE HRSFLSEDGV FVISPLocalizationUniProt · AlphaFold · HPA
Whether an antibody against RNASE9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.4
- Highest tissue expression
- 93 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 93 nTPM
- adipose tissue: 0 nTPM
- adrenal gland: 0 nTPM
- amygdala: 0 nTPM
- appendix: 0 nTPM
- basal ganglia: 0 nTPM
Single-cell type
- epididymal principal cells: 143 nCPM
- epididymal basal cells: 2 nCPM
- epididymal clear cells: 2 nCPM
- mast cells: 1 nCPM
- epididymal efferent duct ciliated cells: 0.4 nCPM
- pericytes: 0.4 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- amygdala: 0 nTPM
- basal ganglia: 0 nTPM
- cerebellum: 0 nTPM
- cerebral cortex: 0 nTPM
- choroid plexus: 0 nTPM
- hippocampal formation: 0 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.83
- gnomAD pLI
- 0.34
- gnomAD missense Z
- -0.13
- DepMap mean gene effect
- 0.04
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RNASE9 as an antibody target. Whether an autoantibody or antibody against RNASE9 could matter depends on whether native RNASE9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RNASE9 is annotated as secreted, so native RNASE9 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label RNASE9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...